KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-cash Items: 2015-2025

Historic Non-cash Items for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Sep 2025 value amounting to $4.6 million.

  • CRISPR Therapeutics AG's Non-cash Items fell 3.16% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 3.16%. This contributed to the annual value of $14.1 million for FY2024, which is 87.85% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Non-cash Items of $4.6 million as of Q3 2025, which was down 7.20% from $5.0 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Non-cash Items peaked at $219.1 million during Q4 2021, and registered a low of $4.0 million during Q1 2021.
  • Moreover, its 3-year median value for Non-cash Items was $5.0 million (2025), whereas its average is $31.9 million.
  • In the last 5 years, CRISPR Therapeutics AG's Non-cash Items soared by 3,876.89% in 2022 and then plummeted by 96.92% in 2023.
  • Quarterly analysis of 5 years shows CRISPR Therapeutics AG's Non-cash Items stood at $219.1 million in 2021, then slumped by 85.34% to $32.1 million in 2022, then surged by 260.03% to $115.7 million in 2023, then slumped by 87.85% to $14.1 million in 2024, then decreased by 3.16% to $4.6 million in 2025.
  • Its Non-cash Items was $4.6 million in Q3 2025, compared to $5.0 million in Q2 2025 and $5.0 million in Q1 2025.